Gene therapy and cement injection for the treatment of hip prosthesis loosening in elderly patients Poorter, J. de

Four patients without diabetes had grade 1 or 2 hyper- glycaemia 1 to 3 days after vector injection once (Patient 10, glucose 8.4 mmol/litre 1 day after vector injection; patient

Figure 1 shows the mean increase in cement mantle thickness per Gruen zone and per dose group, after cement injection compared with the inclusion period.. In Figure 1

In a previous study we performed percutaneous periprosthetic cement injection in elderly patients with aseptic loosening of the hip after gene directed en- zyme prodrug therapy

For the removal of the interface tissue between prosthesis and bone a gene-directed enzyme prodrug therapy (the vector CTL102 in combination with the prodrug CB1954) is used..

Voor het verwijderen van het interface weefsel tussen de prothese en het bot wordt een gene-directed enzyme prodrug therapie (de vector CTL102 in combinatie met de prodrug

Towards gene therapy in prosthesis loosening: efficient killing of inter- face cells by gene-directed enzyme prodrug therapy with nitroreductase and the prodrug CB1954..

In 2002 begon Jolanda als onderzoeker aan haar promotie-onderzoek in het Leids Uni- versitair Medisch Centrum onder begeleiding van Prof. De uit- voering van het onderzoek

Gene therapy and cement injection for the treatment of hip prosthesis loosening in elderly patients..